Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) CTO Jay S. Stout sold 7,239 shares of the business’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $28.90, for a total value of $209,207.10. Following the sale, the chief technology officer now owns 147,739 shares in the company, valued at $4,269,657.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Immunovant Stock Performance
Shares of Immunovant stock opened at $27.17 on Friday. The stock’s 50-day simple moving average is $32.10 and its 200-day simple moving average is $35.79. Immunovant, Inc. has a 52 week low of $15.90 and a 52 week high of $45.58.
Immunovant (NASDAQ:IMVT – Get Free Report) last announced its quarterly earnings data on Monday, February 12th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. Research analysts predict that Immunovant, Inc. will post -1.7 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on IMVT
Hedge Funds Weigh In On Immunovant
Large investors have recently made changes to their positions in the business. Headlands Technologies LLC purchased a new position in shares of Immunovant in the fourth quarter valued at about $27,000. Assetmark Inc. purchased a new stake in shares of Immunovant in the fourth quarter worth about $61,000. Barclays PLC lifted its position in shares of Immunovant by 2,558.1% in the second quarter. Barclays PLC now owns 2,286 shares of the company’s stock worth $43,000 after buying an additional 2,200 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Immunovant by 96.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,360 shares of the company’s stock worth $129,000 after buying an additional 1,651 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Immunovant in the fourth quarter worth about $212,000. 47.08% of the stock is currently owned by hedge funds and other institutional investors.
About Immunovant
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Recommended Stories
- Five stocks we like better than Immunovant
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 Stocks Leading the U.S. Agriculture Comeback
- Canada Bond Market Holiday: How to Invest and Trade
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What is the Euro STOXX 50 Index?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.